top of page

Eli Lilly's Rheumatoid Arthritis Drug Accelerates Recovery in COVID-19 Patients

(Reuters) - Eli Lilly and Co said on Monday its rheumatoid arthritis drug shortened the recovery time for hospitalized COVID-19 patients also given Gilead Sciences Inc's antiviral remdesivir.

Lilly said its drug, baricitinib, branded as Olumiant, in combination with remdesivir cut the median recovery time by about a day, compared to patients treated with remdesivir alone.

Remdesivir has been at the forefront of the fight against COVID-19 after the drug was granted an emergency use authorization (EUA) in May on the basis of trial data that showed it helped shorten hospital recovery time.

While vaccines are seen as essential in controlling the pandemic, experts say treatments are needed to control the severity of the respiratory disease caused by the new coronavirus.


Read more here : https://www.medscape.com/viewarticle/937315?src=mkm_covid_update_200914_mscpedit_&uac=218819SG&impID=2564748&faf=1

2 views0 comments

Recent Posts

See All
bottom of page